Study of Citrate and Bivalirudin for Anticoagulation during Continuous Renal Replacement Therapy (CRRT) in Critically Ill Patients with Acute Kidney Injury (AKI)
作者
Deepak Malviya,M. K. Tripathi,Hemant Agarwal,Deepak Yadava
PRIMARY OBJECTIVE: To study the filter life span using Citrate and Bivalirudin as anticoagulation agent in CRRT. SECONDARY OBJECTIVE: To study the length of stay in ICU. To study the bleeding and other complication of CRRT. To study transfusion requirement. MATERIALS AND METHODS: Study area: Department of Anaesthesiology and critical care medicine, DrRML IMS, Lucknow. Sample size: 40. Sampling technique: Consecutive sampling- Patients admitted in ICU, diagnosed with AKI and need CRRT. Study design: Prospective & Quasi-experimental (non-randomized) study design. Study duration: 18 months. Sample size calculation: Based on anticipated value of mean Filter life Span in two groups (Bivalirudin Vs Citrate) based on previous studies as in Bivalirudin* group 29.6 (SD 20.7) and in Citrate(#) group 49 (SD 29) with α of 0.05, Beta 0.2, at 80% power the total sample size is 36. In order to compensate for the dropouts the sample size is 40. (20 in each group). RESULTS: For CRRT, Regional citrate anticoagulation (RCA) has more hemofilter survival time as compare to Bivalirudin. (P<0.001). In view of length of ICU stay there was no significant difference in between RCA and bivalirudin (p = 0.705). There was no significant changes in APACHE II score DURING CRRT and POST CRRT with both RCA and bivalirudin. Both RCA and Bivalirudin significantly decreased Serum urea and Serum creatinine level (p<0.001), from PRE CRRT to DURING CRRT and from PRE CRRT to POST CRRT. However there was no significant difference in serum urea and serum creatinine level in between RCA and Bivalirudin. There was significant increase in 24 hour urine output from PRE CRRT to DURING CRRT and from PRE CRRT to POST CRRT with both RCA and Bivalirudin but there was no significant difference in 24 hour urine output in between RCA and Bivalirudin. There was no significant differences in Hb, Platelet count, s.albumin, PT, INR at PRE CRRT, DURING CRRT and POST CRRT in between RCA and Bivalirudin. There was no significant bleeding complication observed during and after CRRT with both RCA and bivalirudin. There was no significant difference between RCA and Bivalirudin for PRBC, SDP or RDP, and FFP transfusion. There was no significant difference of Mean Arterial Pressure during CRRT and post CRRT in between RCA and Bivalirudin group. There was no significant difference in survival status of patient after 24 hours of completion of CRRT between RCA and Bivalirudin. CONCLUSION: After observing the data and statistical evalution, its concluded that Regional citrate anticoagulation (RCA) has better hemofilter life span than bivalirudin and recommended the use of RCA for better hemofilter survival time whenever systemic anticoagulation contraindicated.